Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6–17 years: Final results of a phase 2, single-blind, randomised controlled trial (COV006).
Saved in:
| Title: | Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6–17 years: Final results of a phase 2, single-blind, randomised controlled trial (COV006). |
|---|---|
| Authors: | Li, Grace1 (AUTHOR) g.li@nhs.net, Marchevsky, Natalie G.1 (AUTHOR), Macaulay, Grace1 (AUTHOR), Aley, Parvinder1 (AUTHOR), Baughan, Hannah1 (AUTHOR), Plested, Emma1 (AUTHOR), Bibi, Sagida1 (AUTHOR), Cappuccini, Federica1 (AUTHOR), Faust, Saul N.2 (AUTHOR), Heath, Paul T.3 (AUTHOR), Muller, Jill1 (AUTHOR), Robinson, Hannah1 (AUTHOR), Roderick, Marion4 (AUTHOR), Snape, Matthew1 (AUTHOR), Smith, David1 (AUTHOR), Song, Rinn1 (AUTHOR), Liu, Xinxue1 (AUTHOR), Lambe, Teresa1,5 (AUTHOR), Pollard, Andrew J.1,6 (AUTHOR) |
| Source: | Vaccine. Aug2025, Vol. 62, pN.PAG-N.PAG. 1p. |
| Database: | Environment Complete |
Be the first to leave a comment!
